

## **Post Authorisation Assessments**

## Ubropen 600 mg Intramammary Suspension for Lactating Cows Vm 42810/4000

	00.14 000.4	
•	08 May 2024	Introduction of a summary of the PSMF or changes to
		the summary of the PSMF not already covered
	40. h.m.s. 0000	elsewhere in this Annex. (NI)
•	13 June 2023	Addition of a secondary packaging site of a finished
		product. (NI)
•	22 December 2022	Change in the manufacturing process of the finished
		product, including an intermediate used in the
		manufacture of the finished product:
		Change to in-process tests or limits applied during the
		manufacture of the finished product:
•	22 December 2022	Variation to update the ASMF.
•	11 October 2022	Addition of a new in-process test and limits applied
		during the manufacture of the finished product.
•	16 June 2022	Addition of a secondary packaging site of a finished
		product.
•	19 May 2021	Submission of an updated Ph. Eur. certificate of
		suitability for an active substance from an already
	(= )	approved manufacturer.
•	15 April 2021	Renewal – UK as CMS.
•	06 July 2020	Repeat Use MRP to add 4 new member states
•	01 February 2019	Change in distributor details. From Vetcare Oy, P.O. Box
		99, 24101 Salo, Finland to Boehringer Ingelheim Animal
		Health UK Ltd, Ellesfield Avenue, Bracknell, Berkshire,
		RG12 8YS, United Kingdom.
•	23 October 2018	Addition of a supplier of packaging components or
		devices.
		Replacement of a specification parameter of the finished
		product.
•	14 September 2018	Addition of a manufacturer responsible for batch release
		including batch control/testing.
		Addition of a secondary packaging site of the finished
		product.
		Addition of a test procedure for the finished product.
		Addition of test method on the finished product
		specifications.
		Addition of a manufacturing site for part of the manufacturing process of the finished product.
		Addition of a manufacturing site of the finished product.
	00 May 2019	Addition of a manufacturer of the active substance or
•	09 May 2018	addition of a site of manufacture.
	27 Sontombor 2017	
•	27 September 2017	Addition of a site where batch control/testing takes place.
		Change in the sterilising method of the final product.

•	19 July 2017	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS. Changes to the DDPS.
•	26 May 2017	Increase in the shelf-life of the finished product as packaged for sale, from 1 year to 2 years.
•	24 May 2017	Change in the invented name of the veterinary medicinal product from Caremast Vet 600 mg Intramammary Suspension for Lactating Cows to Ubropen 600 mg Intramammary Suspension for Lactating Cows.